

Supplementary Table 2. Shear-wave velocity of each tumor according to participants' group: subgroup analysis according to base chemotherapeutic agent

	FOLFOX (n=51)			FOLFIRI (n=16)		
	Responder group (n=24)	Non-responder group (n=27)	P-value	Responder group (n=10)	Non-responder group (n=6)	P-value
First set SWV (m/s)	2.58 (1.00 to 4.55)	2.35 (0.57 to 4.55)	0.396	3.20 (0.59 to 4.03)	1.98 (0.64 to 3.13)	0.083
Second set SWV (m/s)	1.82 (0.79 to 4.10)	2.65 (0.65 to 4.35)	0.278	2.73 (0.57 to 4.08)	2.05 (0.71 to 3.64)	0.588
Change in SWV (%)	-18.4 (-58.4 to 28.6)	6.1 (-51.1 to 43.9)	<0.001	-16.3 (-62.4 to -0.24)	9.0 (-0.49 to 16.5)	0.002

Values are presented as median (range).

FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; SWV, shear-wave velocity.

Supplementary Table 3. Shear-wave velocity of each tumor according to participants' group: subgroup analysis according to the addition of targeted agent

	FOLFOLX or FOLFIRI only (n=20)			FOLFOLX or FOLFIRI+bevacizumab (n=23)			FOLFOLX or FOLFIRI+cetuximab (n=24)		
	Responder group (n=7)	Non-responder group (n=13)	P-value	Responder group (n=10)	Non-responder group (n=13)	P value	Responder group (n=17)	Non-responder group (n=7)	P-value
First set SWV (m/s)	3.73 (2.07 to 4.09)	2.30 (0.73 to 4.55)	0.057	1.94 (0.59 to 3.68)	2.35 (0.57 to 4.22)	0.352	2.88 (1.00 to 4.55)	0.83 (0.64 to 3.59)	0.136
Second set SWV (m/s)	2.45 (1.03 to 4.08)	2.65 (0.77 to 4.35)	0.905	1.23 (0.57 to 3.32)	2.40 (0.65 to 4.35)	0.072	2.59 (0.82 to 4.10)	0.93 (0.71 to 3.72)	0.589
Change in SWV (%)	-26.9 (-50.4 to -0.24)	5.48 (-12.4 to 43.9)	0.002	-13.7 (-58.4 to 5.74)	7.3 (-51.1 to 21.9)	0.001	-18.0 (-62.4 to 28.6)	10.9 (-8.08 to 31.4)	0.020

Values are presented as median (range).

FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; SWV, shear-wave velocity.

Supplementary Table 4. Prediction of treatment response: subgroup analysis according to chemotherapeutic regimen

	Base chemotherapeutic agent		Addition of targeted agent		
	FOLFOX (n=51)	FOLFIRI (n=16)	FOLFOLX or FOLFIRI only (n=20)	FOLFOLX or FOLFIRI+ bevacizumab (n=23)	FOLFOLX or FOLFIRI+ cetuximab (n=24)
Area under the curve	0.798 (0.662-0.897)	0.983 (0.766-1.000)	0.934 (0.729-0.996)	0.908 (0.713-0.988)	0.807 (0.595-0.938)
Cutoff value	>-16.0	>-3.4	>-13.0	>1.1	>-18.0
Sensitivity	96.3 (81.0-99.9)	100.0 (54.1-100.0)	100.0 (75.3-100.0)	92.3 (64.0-99.8)	100.0 (59.0-100.0)
Specificity	58.3 (36.6-77.9)	90.0 (55.5-99.7)	85.7 (42.1-99.6)	90.0 (55.5-99.7)	52.9 (27.8-77.0)
Positive predictive value	72.2 (61.7-80.8)	85.7 (48.3-97.5)	92.9 (67.9-98.8)	92.3 (65.0-98.7)	46.7 (34.6-59.2)
Negative predictive value	93.3 (66.5-99.0)	100.0	100.0	90.0 (57.5-98.4)	100.0
Accuracy	78.4 (64.7-88.7)	93.8 (69.8-99.8)	95.0 (75.1-99.9)	91.3 (72.0-98.9)	66.7 (44.7-84.4)

Value in parentheses indicate 95% confidence interval.

FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan.